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Is increased erythrocyte sodium-lithium countertransport a useful
marker for diabetic nephropathy? Genetic predisposition to essential
hypertension has been proposed as a risk factor for the development of
diabetic nephropathy in type 1 (insulin-dependent) diabetes mellitus.
An increased sodium-lithium countertransport activity (NaLiCT) has
been suggested as a genetic marker for essential hypertension. We
therefore evaluated NaLiCT in diabetic patients with (N = 39) or
without (N 23) diabetic nephropathy (DNP), patients with non-
diabetic renal diseases (N = 42) and in healthy controls (N = 24). The
NaLiCT was elevated in both diabetic patient groups compared to
healthy controls (median 244; range 134 to 390 mol liter
cells' hr), but was not different in patients with DNP (median 314;
range 162 to 676), without DNP (median 325; range 189 to 627) and
patients with non-diabetic renal disease (median 300; range 142 to 655).
The genetic predisposition to DNP is illustrated by the fact that diabetic
sibs of probands with DNP showed a higher occurrence of DNP than
diabetic sibs of patients without DNP. We analyzed whether familial
DNP clustered with an increased NaLiCT. The NaLiCT in sibs con-
cordant for the presence of DNP (N = 10; median 307; range 217 to 428
mo1 liter cel1s' hC') was not significantly different from that in
sibs concordant for absence of DNP (N = 15; median 279; range 189 to
442). We conclude that erythrocyte sodium-lithium countertransport
activity cannot be used as a marker to identify patients at risk for the
development of diabetic nephropathy.
Approximately one third of the patients with type 1 (insulin-
dependent) diabetes mellitus develop the clinical syndrome of
diabetic nephropathy (DNP), mostly 15 to 20 years after the
onset of diabetes [1]. The development of DNP is heralded by
microalbuminuria and a rise in blood pressure [2]. At present
there are no explanations why some patients develop DNP and
others do not [1, 3]. The susceptibility to DNP cannot solely be
explained by differences in glycemic control [4], which suggests
that other factors are involved. Even at the early stages, DNP
is accompanied by a rise in blood pressure [5], and some
authors have already observed such a rise before any impair-
ment of kidney function was detectable [2, 6]. Others, however,
argue that the rise in blood pressure is rather the consequence
of DNP than a causative factor [7].
Recently, Viberti, Keen and Wiseman have found that non-
diabetic parents of patients with DNP had higher blood pressure
levels, suggesting that a familial predisposition to hypertension
is a risk factor for the development of DNP [8]. This contention
was corroborated by findings of two independent groups of
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investigators, who showed that erythrocyte sodium-lithium coun-
tertransport activity (NaLiCT), a genetic marker for essential
hypertension in non-diabetic patients [9], is increased in patients
with overt DNP compared to diabetics without DNP [10, 11] and
patients with non-diabetic renal disease [11]. Subsequently, an
increased NaL1CT was also found in patients with microalbumin.
ui-ia [12], who are at high risk for progression to overt DNP [6].
Finally, an increased NaLiCT in type 1 diabetic patients with
normoalbuminui-ia and normotension appeared to be associated
with an increased glomerular filtration rate and filtration fraction
[13]. Since hyperfiltration is regarded as one of the possible
pathophysiological mechanisms in the development of DNP, these
findings suggest that patients who are at risk for the developmenl
of DNP can be identified by an increased NaLiCT. Based on these
observations, the concept was formulated that the susceptibility to
DNP in type I diabetes may be associated with a genetic predis-
position to essential hypertension, and that an increased NaLiCT
could be used as a marker to identify patients at risk for DNP. We
measured NaLiCT in patients with type I diabetes with and
without DNP, patients with various non-diabetic renal diseases
and normal healthy control subjects. Furthermore, a second study
was undertaken in which we analyzed NaLiCT in familial diabetes
mellitus. It has been reported that development of DNP is clus-
tered in families, since diabetic sibs of patients with DNP show a
higher frequency of DNP than diabetic sibs of patients without
DNP [141, which supports the hypothesis that genetic factors are
involved in the susceptibility to DNP. We investigated whether
familial DNP clustered with an increased NaLiCT by measuring
NaLiCT in diabetic sibs concordant for the presence or absence of
DNP.
Our results [15, 16] appeared to be at variance with those
mentioned earlier [10, 11], but were similar to those reported
recently by Jensen et al [17]. Like Jensen we used LiHCO3 to
load erythrocytes with lithium, while Krolewski et al [101 and
Mangili et al [11] used LiC1. To exclude that this discrepancy in
NaLiCT activity in DNP was due to differences in methodol-
ogy, we measured NaLiCT after both loading conditions
(LiHCO3 and LiC1) in healthy controls and in diabetic patients
with and without DNP.
Methods
Patients
Study I. To study the relation between NaLiCT and DNP,
patients with and without diabetic nephropathy were recruited
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from the diabetology outpatient clinic. All patients had type I
(insulin-dependent) diabetes mellitus. Duration of diabetes in
the patients without diabetic nephropathy had to be at least 15
years. NaLiCT was also measured in a group of patients with
various non-diabetic renal diseases who were recruited from the
nephrology outpatient clinic. The original renal disease in these
patients was respectively: chronic pyelonephritis (N 5), adult
polycystic kidney disease (N = 6), interstitial nephritis (N = 3),
hypertensive glomerulosclerosis (N = 2), chronic glomerulone-
phritis (N = 3), focal glomerulonephritis (N = 7), Alport's
disease (N = 1), membranous glomerulonephritis (N = 5), IgA
nephropathy (N = 5), and focal and segmental glomeruloscle-
rosis (N = 5). A control group of 24 healthy subjects was also
studied. The control subjects all had a normal blood pressure,
normal renal function and no proteinuria. All studied patients
and controls were Caucasians. The results of this study have
partly been published elsewhere [15]. In this report 11 diabetic
patients were additionally studied.
Study II. To analyze whether familial DNP clusters with an
increased NaLiCT, patients with type 1 diabetes mellitus of at
least 15 years duration who also had a living sib with type 1
diabetes for at least 15 years were identified and enrolled in this
study. The results of the NaLiCT measurements in these
patients are included in study I.
Methods
Diabetic nephropathy is defined as the presence of an albu-
min excretion rate (AER) > 20 g/min in each of two timed,
overnight, sterile, non-ketcic urine collections. Incipient
nephropathy is defined as an AER between 20 and 200 tg/min
and overt nephropathy as an AER > 200 g/min. The albumin
concentration was measured by laser immunonephelometry as
described previously [18] [interassay coefficient of variation:
3% for high (>70 ,tLg/ml) and 10% for low albumin concentra-
tions]. Other kidney or urinary tract diseases were excluded by
clinical or laboratory parameters. In the patients with non-
diabetic renal disease, proteinuria was assessed by measure-
ment of the protein/creatinine ratio (g/mmol of creatinine X 10)
in a fresh morning sample [19]; protein concentration was
measured with the biuret method and creatinine with the Jaffé
method. Blood pressure was measured after five minutes of
recumbency with a standard mercury sphygmomanometer.
Hypertension was defined as a mean arterial pressure (MAP)>
110 mm Hg or the use of antihypertensive drugs, MAP was
calculated as diastolic blood pressure plus one third of the pulse
pressure. In all patients NaLiCT, blood pressure, HbAIC, albu-
min excretion rate (AER), serum creatinine and body weight
were measured. In the diabetic patients serum cholesterol was
also measured. HbAIC was analyzed by HPLC (normal value 4.3
to 6.3%).
Measurement of sodium-lithium countertransport
Venous blood was drawn between 08.00 and 10.00 a.m. and
all measurements were performed on the day of the blood
collection. The blood was collected in two 10 ml heparin-coated
tubes for duplicate measurement of NaLiCT,
Measurement of NaLiCT after loading with lithium bicarbon-
ate. NaLiCT was measured according to the method described
by Ibsen et al [20]. All steps were performed in duplicate. The
whole assay was carried out on ice with cooled (4°C) media,
except for the effiux measurements, which were performed in a
water bath at 37°C. From the blood samples plasma and buffy
coat were removed and the erythrocytes were washed three
times in a magnesium chloride medium (75 m magnesium
chloride, 85 m sucrose, 10 m glucose, 10 mM Tris-MOPS,
pH 7.4) and after centrifugation (5 mm 1500 g at 4°C) resus-
pended in the lithium loading medium (150 mi lithium bicar-
bonate, 5 m potassium chloride, 10 m glucose) to a hema-
tocrit of 20%. The medium was made from lithium carbonate
and titrated with CO2 to pH 7.4. The erythrocytes were
incubated in this medium during 20 minutes at 37°C. After
loading, the cells were washed five times in a potassium
chloride medium (150 m potassium chloride, 10 m glucose,
0.1 mM ouabain, 10 mrvi Tris-MOPS, pH 7.4). After each wash
step the cells were centrifuged three minutes at 1500 g at 4°C.
After washing a 35% erythrocyte suspension was made in the
potassium medium. A sample was taken for measurement of the
intracellular lithium concentration and for the measurement of
hemoglobin concentration and mean cell hemoglobin concen-
tration (Technicon HI). For the lithium efilux measurements 0.5
ml of the erythrocyte suspension was incubated at 37°C in
parallel in either 3.5 ml sodium chloride medium (150 mM
sodium chloride, 10 m glucose, 0.1 mti ouabain, 10 mM
Tris-MOPS) or in 3.5 ml of the above-mentioned potassium
chloride medium. The hematocrit at which the countertransport
measurement took place was therefore 4%. After 30, 60 and 90
minutes, incubation in either medium was stopped by placing the
tubes on ice for two minutes, and subsequent centrifugation at
1500 g for three minutes at 4°C. Lithium concentration in the
supernatant was measured by atomic absorption spectropho-
tometry (Perkin Elmer 5000). The standard solutions contained
0.25 to 2.5 m lithium.
For the calculation of the NaLiCT, it is assumed that a linear
relation exists between the sodium-simulated lithium efflux over
time. We measured three time points (30, 60 and 90 mm) to
improve accuracy. The slope of this line (Li/t) can be
calculated by linear regression analysis. That our approach
yielded linear kinetics can be derived from the observation that
the mean r value of the separate measurements was 0.9995
0.0006.
The lithium efflux rate (.tmol/liter cells/hr) =
(iLiIt) x (MCHC/Hb) x df x k
where df = dilution factor = 8/21 and
k = constant = 60. l0 mm/hr.
Sodium-lithium countertransport was calculated from the dif-
ference between the lithium effiux rate in the sodium chloride
medium and in the potassium chloride medium. The intra-assay
variation of our assay is 5%, while the inter-assay variation was
13%. This inter-assay variation, representing both inter-test
variability as well as biological variability, was measured by
performing 4 to 6 measurements during a six week period in six
individuals. These figures are comparable to those reported in
the literature [21, 22].
Measurement of NaLiCT after loading with lithium chloride.
This method was carried out by a procedure identical to that
described above except for the loading conditions. Erythro-
cytes were suspended in lithium chloride medium (150 mM
C0
CoI-4-.
Cc.)OL
-I-(o
CoI-
4-aC
lithium chloride, 10 mr'i glucose, 10 mrvi Tris-MOPS) and
incubated for three hours. Thereafter the cells were washed and
effiux measurements were performed in the same way as
mentioned above. In 17 subjects NaLiCT measurements ob-
tained with both methods were compared. In three subjects the
change in intracellular bicarbonate concentration was measured
after loading with LiHCO3 or LiCI and the complete washing
cycle.
Statistical analysis
All results are expressed as mean sn or as median (range)
when the data were not normally distributed. Wilcoxon's rank
sum test for unpaired data was applied for comparison of the
groups. With Bonferroni adjustment for multiple comparisons
the significance level was set at P < 0.01. Correlations were
measured as Spearman's correlation coefficients in all cases.
Comparison of the two methods for measurement of NaLiCT
was performed according to the linear regression analysis of
Passing and Bablok which was developed to compare analytical
procedures [23J.
Results
Validation of NaLICT measurement
Before measurement of the sodium stimulated lithium-efilux
an intracellular lithium concentration should be reached of at
least 5 mmol/liter, since at that concentration the countertrans-
port is saturated [20]. After loading of erythroctyes with
LiHCO3 or with LiCl, we analyzed the intracellular concentra-
tions obtained with both methods. The lithium-influx as a
function of the incubation time is shown in Figure 1. From this
figure it is clear that the critical intracellular lithium concentra-
tion of 5 mmol/liter was reached much faster by loading with
LiHCO3 than by LiCl (20 vs. 180 mm). During incubation with
LiHCO3, Li is transported into the cell as LiCO in exchange
for Cl via the anion exchanger [24], but under these condi-
tions, HCO is also exchanged for C1. To evaluate this change
we measured the change in the intracellular HCO concentra-
tion after loading with LiHCO3 or L1CI. As can be seen in
Figure 2, there was indeed an increase in the intracellular
HCO; concentration after loading with HCO, but during the
wash cycles with KCI this was corrected via the same anion
exchange. At the moment the actual countertransport measure-
Incubation time, minutes
Fig. 3. Lithium-efflux in sodium chloride medium (U/S) and potassium
chloride medium (/O) oferythrocytes loaded in LiHCO3 (•/O) or in
LiCI (•ILJ) as a function of time (mean of 6 measurements).
ment began, the intracellular HCO3 concentration was again
identical to that of cells loaded with LiCI. Also, the intracellular
C1 concentration was identical after the washing procedure in
cells either loaded with LiHCO or LiCI (data not shown).
Measurements of the Li efflux in a KCI medium (spontaneous
lithium leakage) or in a NaCl medium (spontaneous leakage and
sodium-lithium exchange) after loading with LiHCO3 or LiCl
were completely identical (Fig. 3), To further substantiate this,
we measured NaLiCT with both loading procedures in healthy
subjects and in diabetic patients with and without DNP. As can
be seen in Table I the magnitude of the NaLiCT was identical
for both methods. If we compared NaLiCT activities obtained
with the two different loading conditions according to the linear
regression model of Passing and Bablok [23], we found an R2 of
0.97 (Fig. 4), indicating that the two loading procedures yielded
identical results.
NaLiCT and diabetic nephropathy
The clinical and laboratory data of the patients in study I are
shown in Table 2. No difference was found in age or duration of
diabetes in the diabetic patients with or without nephropathy.
There was a male preponderance in the renal disease groups
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Number
L1HCO3 LiCI
p.mol liter cells' hr' P
DNP+
DNP—
Controls
6
5
6
276 (240—601)
277 (22 1—360)
254 (16C—355)
280 (248—608)
304 (232—350)
255 (187—360)
NS
NS
NS
NS is not significant.
(DNP+ and RD). This is in line with the observations that male
sex is prevalent in patients with either diabetic or non-diabetic
renal disease [25]. By definition the patients with DNP had a
higher AER and, as expected, higher serum creatinine levels
and blood pressure readings. Cholesterol levels were equal in
both diabetic groups. From the patients with DNP, 15 patients
had incipient diabetic nephropathy (median AER 72; range 27 to
159 rg/min) and 24 patients had overt diabetic nephropathy
with a median AER of 432 (range 219 to 2846) /.tg/min. In
patients with DNP, the MAP was significantly higher than in
liabetic patients without DNP (P < 0.001). Of the 24 patients
with overt DNP, 15 had hypertension, and one of the patients
with incipient DNP had hypertension. None of the diabetic
patients without DNP had hypertension. Of the patients with
non-diabetic renal disease (RD), 26 had renal disease which was
glomerular in origin and 16 non-glomerular. These two groups
Dnly differed for the magnitude of the proteinuria [median 3.8
(0.1 to 19.7) vs. 0.8 (0.1 to 5.8) g/mmol creatinine; P < 0.011.
Hypertension was present to the same extent in patients with
glomerular RD (21/26, 81%) and in the patients with non-
glomerular RD (13/16, 81%). The blood pressure level was
higher in the non-glomerular group (MAP 112 13 vs. 104 9
mm Hg; P < 0.02). The serum creatinine was significantly
higher in the RD patients than in either group of diabetic
patients. In normal controls the median NaL1CT was 244; range
134 to 390 mol liter cells' hr', NaLiCT was elevated in
all patient groups compared to normal controls. This increase
Table 2. Clinical characteristics and metabolic parameters of patients
with diabetes mellitus without (DNP—) or with nephropathy (DNP+),
patients with non-diabetic renal diseases (RD) and of healthy controls
Creatinine ,amo/Iliter
Protein/creatinine ratio
g/mmol x 10
MAP mm Hg
Prevalence of
hypertension %
Serum cholesterol
mmol/liter
Insulin dose
IU/kg/24 hr
DNP— DNP+ RD Controls
Data are given as mean SD or as median and (range). Abbreviations
are: ND, not determined; NR, not relevant; AER, albumin excretion
rate; MAP, mean arterial blood pressure.
P < 0.01 compared to DNP— and RDb P < 0.01 compared to DNP—
c P < 0.001 compared to DNP+ and DNP—
d p < 0.001 compared to DNP+ and RD
P < 0.001 compared to DNP+
1P < 0.01 compared to DNP—
was only significant for both the diabetic patient groups (P <
0.01). NaL1CT in patients with DNP (median 314; range 162 to
676) was not different from that in patients without DNP
(median 325; range 189 to 627) or RD (median 300; range 142 to
655; Fig. 5). NaLiCT in patients with overt DNP (median 326;
range 162 to 676) was not different from that of patients with
incipient DNP (median 284; range 217 to 649). Also in patients
with glomerular (median 321; range 142 to 614) or non-glomer-
ular renal disease (median 291; range 142 to 655) NaLiCT was
not different. In the two patients with renal disease secondary
to hypertension, NaLiCT was respectively 211 and 271
imol liter cells hr. No correlations were found between
NaLiCT and age, HbAIC, creatinine, AER, body weight, MAP
and total cholesterol (measured only in the diabetic patients).
Of the 16 patients with DNP and hypertension, three (19%) had
a NaLiCT > 400 mol . liter cells' hr (the upper normal
limit), whereas 8 of 23 (35%) of the patients with DNP without
hypertension had a NaLiCT above this limit. This indicates that
hypertension in patients with DNP is not associated with an
increased NaLiCT. Of the 50 patients with hypertension, 47
were receiving antihypertensive therapy. Monotherapy was
used in 23 patients (ACE inhibitors in 7, p-blockers in 10,
diuretics in 3 and calcium entry blockers in 3). A two drug
regimen was used in 20 patients (ACE inhibitors or p-blockers
combined with a diuretic in 2 and 15 patients, respectively, and
a p-blocker combined with a calcium entry blocker in 3 pa-
tients). Triple therapy was used by four patients. The type of
antihypertensive drug or the combination used had no influence
on NaLiCT. Antihypertensive treatment was not discontinued
before the NaLiCT measurement.
Table 1. Sodium-lithium countertransport [median (range)] after
loading of the red cells with LiHCO3 or LiCI in patients with
(DNP+) or without (DNP—) diabetic nephropathy and normal
healthy controls
Number
M/F
Age years
Diabetes duration
years (range)
HbAIC %
AER p.g/min
42
26/16
44 15
NR
23
10/13
43 9
26 8
(18—44)
8.8 1.1
7
(3—19)
83 12
ND
24
9/15
31 8
NR
39
24/15
38 12
24 7
(10—37)
9.1 1.1
258"
(27—2846)
103 38
ND
NR NR
ND ND
399 286C 83 12
2.6 0
(0. 1—19.7)93±5" 101±10 107±l1 8S±8
0 41 81 0
0
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Fig. 4. Comparison of NaLiCT after loading of the erythrocytes with
UHCO3 or LiCI. Given are the regression line and the line of identity
dotted line).
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Fig. 5. Sodium-lithium countertransport
(NaLiCT) in patients without diabetic
nephropathy (DNP—), with diabetic
nephropathy (DNP+), with non-diabetic renal
diseases (RD) and in healthy control subjects
(C). The dots represent the individual values
and the line is the median for each group.
Table 3. Clinical characteristics and metabolic parameters of
probands and sibs concordant (DNP+/+) or discordant (DNP+/—)
for diabetic nephropathy and probands and sibs both without diabetic
nephropathy (DNP—/—)
DNP+/+ DNP+/- DNP-/-
Sib pairs 5 4 7
Number 10 9 15
M/F 4/6 6/3 6/9
Age years (range) 33 4
(27—39)
42 5
(32—50)
46 9
(32—61)
Diabetes duration 25 6 24 7 27 9
years (range) (15—35) (17—39) (18—44)
Ageatonsetof 95a 18±7 19±10
years (2—19) (4—33) (17—39)
HbAIC % 8.6 0.7 9.2 1.3 8.8 Li
AER sg/min (range) 373 49l
(31—1378)
199 302
(4—907)
7 3
(2—12)
Cholesterol mmol/liter 6.5 1.5 6.1 0.8 5.8 0.7
Creatjnine .mol/1iter 113 42' 84 11 82 12
Systolic BP mm Hg 133 15 142 19 133 12
Diastolic BP mm Hg 82 9l 79 10 75 6
Data are given as mean SD; ranges are given in parenthesis.
P < 0.001
bP < 0.05
NaLiCT and familial diabetes
To study whether an elevated NaLiCT clustered with familial
occurrence of DNP 16 probands with long standing (>15 years)
type 1 diabetes mellitus who had at least one sib also with type
1 diabetes mellitus for more than 15 years could be selected.
The eight probands with DNP had nine sibs with diabetes, of
whom five had DNP, in contrast to only one out of nine sibs of
the eight probands without DNP. This increased prevalence of
DNP in sibs of probands with DNP indicates a trend towards
familial clustering of DNP, which however, was not statistically
significant. Table 3 shows the clinical and metabolic data of the
patients studied. Three groups of siblings were formed: one
with probands and sibs concordant for the presence of nephrop-
athy (DNP+/+), a second group with probands and sibs con-
cordant for absence of nephropathy (DNP—/—) and a group
with probands and sibs discordant for nephropathy (DNP+/—).
Age at onset of diabetes was significantly lower in the DNP +1+
group. Diabetes duration was the same in all groups. Diastolic
blood pressure and serum creatinine were also significantly
increased in the DNP+/+ group, The correlation between
NaLiCT in probands and sibs was not significant (r = 0.48; P
0.06), which confirms the weak genetic basis of NaLiCT.
NaLiCT did not differ between DNP+/+ (median 307; range
217 to 428 mol . liter cells' hr') and DNP—/— (median
279; range 189 to 442), but was significantly increased in
DNP+/— (median 468; range 310 to 649; P < 0.02; Fig. 6). The
two highest NaLiCT levels in this group come from a sister and
brother with and without nephropathy, respectively. In two
DNP+/+ families and three DNP—/— families a positive history
of parental hypertension was present. In four families the
history of parental hypertension was not clear (three in the
DNP-/— and one in the DNP+/+). These data do not permit a
conclusion whether hypertension was more prevalent in parents
of sibs with DNP.
Discussion
As already mentioned, it is at present not known which
factors determine the development of nephropathy in Type 1
(insulin-dependent) diabetes mellitus. Although metabolic con-
trol is certainly an important factor [3, 4], it is generally
accepted that other factors are also involved. Recently, the
predisposition to essential hypertension [8, 10, 11] was put
forward as an important risk factor. This was based on the
presence of an increased prevalence of two indicators for a
genetic predisposition to essential hypertension in patients with
DNP: a) hypertension in non-diabetic parents and b) an in-
creased NaLICT. As indicated in Table 4 this increased activity
of NaLiCT was initially reported in patients with overt DNP
[10, 11] and subsequently also in patients with incipient DNP
[12]. Furthermore, it was found that normoalbuminuric diabetic
patients with an increased NaLiCT had evidence for glomerular
hyperfiltration [13]. This led to the conclusion that an increased
NaLiCT might be useful as an early predictor of nephropathy in
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Fig. 6. Sodium-lithium countertransport in
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Table 4. Review of the literature on sodium-lithium countertransport in patients with diabetic nephropathy (DNP+), without nephropathy
(DNP—), non-diabetic renal disease (RD) and in healthy controls
DNP+
Mean SD
DNP-
Mean SD
RD Controls
Mean SDMean SD
Author Loading or median % > or median % > or median % > or median % >
[refi procedure (range) 400 (range) 400 (range) 400 (range) 400
1. Krolewski et al [10] LiCI 510 229
(210—1400)
60 380 162
(20—780)
38 ND — ND —
2. Mangili et al [11] LiCI 550 190
(180—880)
87 330 160
(100—680)
15 310 140
(120—580)
27 280
(120—410)
?
3. Jones et al [12] LiCI 430
(190—750)
55 290
(110—600)
17 ND — ND —
4. Carr et a! [131 LiCI ND — 330
(130-590)
33 ND — 240
(20—390)
0
5.
6.
Jensen et al [17]
Elving et at (this
LiHCO3
LiHCO3
480
(60—1200)
314
71
28
410
(120—750)
325
53
26
ND
300
—
24
310
(180—730)
244
25
0
study)
a % patients with NaLiCT > 400 j.mol
(162—676)
liter ce1ls hr.
(189—627) (142—655) (134—390)
type 1 diabetes. Several mechanisms have been proposed to
explain the association between predisposition to essential
hypertension and DNP [10—12]. It has been hypothesized that
predisposition to essential hypertension is related to genetically
determined abnormalities in renal hemodynamics [26—28].
These derangements in combination with diabetes-associated
alterations in renal hemodynamics, together with poor meta-
bolic control, could then lead to the development of DNP. The
findings of Carr et at [131 are compatible with this contention,
because they could identify within a group of normoalbuminuric
type 1 diabetes a subgroup of patients with hyperfiltration, by
means of an increased NaLiCT. A second explanation that has
been raised for the association between DNP and elevated
NaLiCT is that the NaLiCT activity is at least functionally
related to the sodium-hydrogen antiport [29—3 1]. The activity of
the Na/H antiporter is responsible for the proximal tubular
sodium-reabsorption and regulation of cell pH, cell volume and
vascular tone [30, 31]. If an increased NaLiCT reflects an
elevated activity of the Na/H antiporter, it may be associated
with increased renal sodium retention, leading to an expanded
extracellular volume [32] and increased vascular tone. This idea
is consistent with the finding of sodium retention in some
patients with diabetes [33, 341. Irrespective of the responsible
mechanism, an increased systemic arterial pressure can lead to
an increased intraglomerular pressure because most diabetic pa-
tients show, dependent of their actual metabolic control, a preglo-
merular vasodilation which facilitates the transmission of systemic
hypertension to the glomerular capillaries. This glomerular hyper-
tension aggravates the glomerular alterations secondary to diabe-
tes, and may thereby lead to the full clinical picture of DNP. A
third explanation that has been advocated is that an increased
NaLiCT is a marker for an increased peripheral insulin resistance
[35], which itself is associated with hyperlipidemia, hypertension
and increased cardiovascular mortality [36]. Furthermore, an
increased NaLiCT is associated with higher levels of cholesterol
and VLDL-triglycerides and with lower levels of HDL-cholesterol
[37—39]. This more atherogenic lipoprotein profile may be a
permissive factor for the development of DNP.
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The enthusiasm about the initial idea that an increased
NaLiCT might be useful to identify patients at risk for the
development of DNP has been tempered by more recent
findings. Our study does not confirm the findings of the initial
reports [10—13]. We found no differences in NaL1CT between
patients with or without DNP, and with non-diabetic patients
with other renal diseases, although patients with diabetes
mellitus had higher NaL1CT values than healthy control sub-
jects. Since the majority of the patients in the initial studies had
overt DNP and hypertension, we analyzed whether patients
with hypertension or overt DNP had higher NaLiCT activity.
This was found not to be the case. After we had finished our
studies [15, 161 results were published by English and Danish
investigators on the relation between a genetic predisposition to
hypertension and the occurrence of DNP [17, 40]. In contrast to
earlier observations [81 no difference was found in blood
pressure of parents of diabetic patients with DNP, compared to
parents of patients without DNP. In both studies a significant,
although weak, correlation was found between NaLiCT in
parents and children, in agreement with the presence of genetic
determinants in NaLiCT. However, the results of NaLiCT
measurements in these two studies were quite different. In the
study of Walker, Tariq and Viberti [40] patients with and
without DNP showed a clear difference in NaLiCT, whereas
Jensen et al [17] could not find a difference in this respect, either
when patients with or without DNP, or when parents of diabetic
patients with or without DNP were compared. In the latter
study, all patients had a higher activity of NaL1CT than healthy
controls. Our study as well as the studies of Jensen et al [17] and
Gall et al [41] (in type 2 diabetic patients) do not confirm that an
increased NaLiCT is a genetic risk marker for the development
of DNP. This is further substantiated by our finding in familial
DNP, in which sib pairs concordant for the presence of DNP
had the same magnitude of NaLiCT as sib pairs concordant for
the absence of DNP. So, even in patients in whom the occur-
rence of DNP is clearly genetically determined, NaLiCT cannot
be used as a marker for DNP.
Theoretically these differences in results might be due to
differences in methodology of NaLiCT measurement. Several
methods are used to measure NaLiCT, which vary especially
for the procedure used to load the erythrocytes with lithium,
that is: a) loading with 150 misi LiC1 [9, 11—13]; b) loading with
10 mri LiC1 and nystatin [10] or c) loading with 150 mivi LiHCO3
[this study, 17, 41]. The disadvantage of loading the erythro-
cytes with LiCl is that it takes three hours before the intracel-
lular lithium concentration is above 5 mmol liter cells '(Fig.
1), at which concentration the NaLiCT is saturated [20]. By
adding nystatin to the incubation medium, the lithium influx is
enhanced, because nystatin disturbs the integrity of the cell
membrane and thereby increases the permeability for ions. It is
not known whether this rather drastic procedure might have an
effect on the function of the delicate transmembrane transport-
ers. We therefore chose LiHCO3 as loading medium, as orig-
inally described by Ibsen et al [20]. Using these conditions
lithium is transported into the cell via anion exchange [24]. This
is a much faster process than exchange diffusion, which takes
place during loading with LiCI. A second difference between
our method and those applied by others [10—131 is that the
sodium independent efflux is measured in a KC1 medium instead
of a MgCl2 medium as originally described by Canessa et at [9].
Previous studies by Ibsen et al [20] have shown that this
sodium-independent spontaneous lithium efflux is identical in
KC1, MgCI2 and choline chloride medium. In the first four
studies listed in Table 4, showing that the NaLiCT was elevated
in DNP, LiCl was used as loading medium, whereas in the last
two studies, in which LiHCO3 was used, no differences be-
tween patients with and without DNP were found. This might
suggest that the outcome of these studies is influenced by the
method used to measure NaLiCT. Several observations, how-
ever, indicate that both methods are equally reliable. First, our
value for NaLiCT in normal controls is comparable to that
reported in the literature (Table 4) [22]. Second, both loading
procedures achieve an intracellular lithium concentration above
the critical value at which the countertransport is saturated [201.
The final proof that differences in methodology are not respon-
sible for the observed differences in results, comes from our
observation that the NaLiCT measured after both loading
procedures is identical (Table 1, Fig. 4).
We cannot offer a clear explanation for the differences in
results. If one analyzes the different studies with regard to the
proportion of patients who have a NaLiCT above the upper
limit of normal controls, that is, 400 mol liter cells' hr'
(Table 4), one finds identical values in patients with non-
diabetic renal diseases (studies 2 and 6) and in patients without
DNP (studies ito 4 and 6) except for study 5. In the last study,
however, the median value for the NaLiCT is rather high in all
groups, and a considerable proportion of the normal controls
(25%) has a NaLiCT above 400 mol liter cells hr'. This
discrepancy might be explained by a difference in time of blood
sampling. In the Danish study, blood was collected in the
afternoon. It was recently reported that NaLiCT has a diurnal
rhythm, the activity increasing during the day [42]. The major
difference for the proportion of patients with a NaLiCT > 400
mo1 liter cells hr' in the various studies listed in Table
4, is observed in patients with diabetic nephropathy. It is known
that NaLiCT can be influenced by several exogenous factors
such as oral contraceptives, hypokalemia [43], pregnancy [441,
thyroid hormones [45], factors that influence the intracellular
calcium concentration [46], exercise [47], lead [48], prednisone
[491, and most importantly, lipid profiles [38, 39]. Recently, it
was shown that LDL-apheresis induces an acute change in
NaLiCT [50]. Although it has been claimed that impaired
kidney function can increase NaL1CT [51,52], others could not
confirm these data [53, 54]. Since the NaLiCT in our group of
patients with non-diabetic renal disease was comparable to that
in patients without DNP, irrespective of a much higher serum
creatinine in the first group, impaired kidney function can be
excluded as an important factor influencing NaLiCT. Differ-
ences in lipid profiles might be an explanation for the differ-
ences observed with regard to NaLiCT in DNP. It is known that
serum lipid profiles [38, 391, as well as the lipid composition of
the cell membrane [55] influence NaLiCT. The importance of
this is reflected by a recent study of Jones et a! [12], who
concluded that in inicroalbuminuric diabetic patients, NaLiCT
is related to total and VLDL triglycerides independent of
HbA,, AER, insulin dose and body mass index. They did not
analyze whether NaLiCT was still elevated in microalbuminuric
patients when differences in the lipid profile were taken into
account. It is known that even in microalbuminuric patients the
lipid profiles are disturbed [56]. In most [10, 11, 13, this studyl,
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Table 5. Influence of low sodium diet (3 g NaCllday) and high
sodium diet (12 g NaCI/day) on urinary sodium excretion (UNaV)
fractional sodium excretion (FENa), fractional lithium excretion
(FELl) and sodium-lithium countertransport (NaLiCT) in 10 normal
controls
Low salt High salt
UNaV mmol/24 hr 27 15 245 41
FENa % 0.28 0.17 1.06 0.3la
FELl % 25.0 5.5 32.5 14.5a
NaLiCT ,wnol - liter 257 55 243 38
cells' hr'
Data are given as mean SD.
a < 0.01
but not all studies [12, 171 on the relation between NaLiCT and
DNP no correlation was found between MAP and/or anti-
hypertensive treatment and the magnitude of the NaLiCT. By
contrast this correlation is in general present in patients with
essential hypertension [57, 58]. This difference is remarkable
and again raises the possibility that the increase in NaLiCT in
DNP found by some investigators is secondary to non-genetic,
exogenous factors. Unfortunately, our studies were not de-
signed to study the potential effect of exogenous factors on
NaLiCT, therefore we cannot evaluate a possible contribution
of the various mentioned factors on the magnitude of the
NaLiCT in our patients.
After the finding that the NaLiCT was elevated in DNP, the
hypothesis has been put forth that this was an indicator for an
increased activity of the sodium-proton exchanger in the renal
proximal tubule. In essential hypertension an inverse correla-
tion was described between red cell NaLiCT and fractional
lithium excretion (FELl) [32], an indicator for proximal tubular
sodium reabsorption [59]. In vitro studies, however, have
shown that both cation transport systems show a differential
sensitivity to amiloride, the Na/H antiporter being sensitive
in contrast to NaLiCT [60, 61]. We analyzed the relation
between NaLiCT and FEL. by measuring both parameters in
healthy volunteers after high and low dietary salt intake [62]. As
expected the FELl was clearly influenced by the amount of
dietary salt intake (Table 5), but the NaLiCT was not influ-
enced. During high and low salt intake both, we found no
correlation between NaLiCT and FELl, while FELl was signif-
icantly correlated with the fractional sodium excretion under
both diet regimens (r 0.65; P < 0.05). This confirms earlier
studies in which no relation was found between NaLiCT and
proximal tubular sodium handling [29, 63, 64]. These in vitro
and in vivo findings do not support the hypothesis that NaLiCT
is functionally related to proximal tubular Na/H exchange.
This is further substantiated by the very recent finding that
NaLiCT is not linked to the Na/H antiporter gene [65],
In conclusion, NaLiCT is increased in patients with type 1
diabetes mellitus, probably due to exogenous factors. It cannot
be used, however, to detect patients at risk for the development
of diabetic nephropathy in these patients.
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